Skip to main content
Retour
MD logo

Pediatrix Medical Group, Inc.

Qualité des données : 100%
MD
NYSE Healthcare Medical - Care Facilities
20,60 €
▲ 0,90 € (4,57%)
Cap. Boursière : 1,77B
Fourchette du Jour
19,92 € 20,74 €
Fourchette 52 Semaines
11,84 € 24,99 €
Volume
902 623
Moyenne 50J / 200J
20,72 € / 18,21 €
Clôture Précédente
19,70 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (626 pairs)

Métrique Action Médiane du Secteur
P/E 10,7 0,4
P/B 2,0 2,9
ROE % 20,3 3,8
Net Margin % 8,6 3,9
Rev Growth 5Y % 0,0 10,0
D/E 0,8 0,2

Objectif de Cours des Analystes

Hold
20,67 € +0.3%
Low: 19,00 € High: 22,00 €
P/E Prévisionnel
9,2
BPA Prévisionnel
2,24 €
Croissance BPA (est.)
+0,0%
CA Est.
1,9 B

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2029 2,05 €
2,01 € – 2,09 €
2,2 B 1
FY2028 2,27 €
2,07 € – 2,41 €
2,1 B 3
FY2027 2,33 €
2,21 € – 2,44 €
2 B 5

Points Clés

Revenue grew 0,03% annually over 5 years — modest growth
ROE of 20,28% indicates high profitability
Generating 252,63M in free cash flow
P/E of 10,70 — trading at a low valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 4,95%
Cash machine — converts 152,75% of earnings into free cash flow

Croissance

Revenue Growth (5Y)
0,03%
Revenue (1Y)-4,92%
Earnings (1Y)N/A
FCF Growth (3Y)55,86%

Qualité

Return on Equity
20,28%
ROIC11,36%
Net Margin8,64%
Op. Margin12,07%

Sécurité

Debt / Equity
0,76
Current Ratio1,66
Interest Coverage6,43

Valorisation

P/E Ratio
10,70
P/B Ratio2,04
EV/EBITDA8,89
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -4,92% Revenue Growth (3Y) -2,05%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 0,03% Earnings Growth (5Y) 6,01%
Profitability
Revenue (TTM) 1,91B Net Income (TTM) 165,39M
ROE 20,28% ROA 7,36%
Gross Margin 24,66% Operating Margin 12,07%
Net Margin 8,64% Free Cash Flow (TTM) 252,63M
ROIC 11,36% FCF Growth (3Y) 55,86%
Safety
Debt / Equity 0,76 Current Ratio 1,66
Interest Coverage 6,43 Dividend Yield 0,00%
Valuation
P/E Ratio 10,70 P/B Ratio 2,04
P/S Ratio 0,92 PEG Ratio -0,04
EV/EBITDA 8,89 Dividend Yield 0,00%
Market Cap 1,77B Enterprise Value 2,05B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1,91B 2,01B 1,99B 1,97B 1,91B
Net Income 165,39M -99,07M -60,41M 66,34M 130,96M
EPS (Diluted) 1,94 -1,19 -0,73 0,79 1,52
Gross Profit 471,88M 454,34M 421,57M 467,03M 513,24M
Operating Income 231,09M -68,71M 7,32M 172,69M 202,92M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 2,25B 2,15B 2,22B 2,35B 2,72B
Total Liabilities 1,38B 1,39B 1,37B 1,46B 1,83B
Shareholders' Equity 865,85M 764,94M 849,06M 891,63M 896,49M
Total Debt 660,30M 662,31M 701,65M 717,08M 1,07B
Cash & Equivalents 375,24M 229,94M 73,26M 9,82M 387,39M
Current Assets 763,51M 639,61M 483,45M 427,99M 840,56M
Current Liabilities 458,91M 434,11M 388,95M 426,98M 427,37M

Scores de Stratégies

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
#449 of 658
17

Activité Récente

Entré Contrarian Investing (David Dreman)
Mar 24, 2026